Aspira Women’s Health Inc.

35 Nutmeg Drive, Suite 260
Trumbull, CT 06611

Website: https://aspirawh.com/

Email: jsullivan@aspirawh.com

General Information:

Aspira Women’s Health Inc. is transforming gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.    

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite^SM, which includes OvaWatch^SM, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus^® combines our FDA-cleared products, Ova1^®and Overa^®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery.    

EndoCheck^SM, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.